17 Nov 2010 07:00
17th November 2010
Plethora Solutions Holdings plc
("Plethora" or "the Company")
Change of advisors
Plethora Solutions Holdings plc (AIM: PLE), the UK-based speciality pharmaceutical company, announces that it has changed financial advisors with immediate effect.
Daniel Stewart & Company plc have been appointed as the Company's Nominated Advisor and as its Joint Broker. In addition, Hybridan LLP has been appointed as Joint Broker.
-Ends-
Enquiries:
Plethora Solutions Steven Powell/Ronald Openshaw | Tel : +44(0) 20 3077 5400 |
Daniel Stewart Antony Legge(Nomad) Martin Lampshire(Broker) | Tel : +44(0) 20 7776 6550
|
Hybridan LLP Claire Louise Noyce | Tel: +44(0) 20 7947 4350
|
About Plethora:
Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder (PSD506), stress urinary incontinence (PSD503), interstitial cystitis (PSD597), gynaecological pain (PSD508), erectile dysfunction (PSD510) and premature ejaculation (PSD502). Plethora's subsidiary, The Urology Company Limited, was established in 2009 to market and distribute a range of therapeutic products for the treatment of urology, andrology and obstetric conditions. The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L).
Further information is available at www.plethorasolutions.co.uk.
Plethora Solutions Holdings Plc (PLE)